BPC-157

BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids, originally derived as a partial sequence from human gastric juice. It belongs to a class of compounds known as body protection compounds and has been the subject of extensive preclinical research since the early 1990s. In animal models, BPC-157 has demonstrated a broad spectrum of biological activities, including the acceleration of wound healing in muscle, tendon, ligament, and skin tissue. Its mechanism of action is believed to involve modulation of the nitric oxide (NO) system, upregulation of growth factor expression (including VEGF and EGF), and interaction with multiple molecular pathways including the FAK-paxillin and JAK-2/STAT-3 signaling cascades.

A substantial body of preclinical literature supports the peptide's role in gastrointestinal cytoprotection. Studies have shown that BPC-157 can counteract lesions induced by NSAIDs, alcohol, and various cytotoxic agents throughout the gastrointestinal tract, from the esophagus to the colon. The peptide appears to promote angiogenesis — the formation of new blood vessels — which is considered central to its healing properties. Research by Sikiric and colleagues has documented its ability to accelerate the healing of anastomoses, fistulas, and other surgical wounds in rat models.

Beyond the gastrointestinal system, BPC-157 has been investigated for neuroprotective effects. Preclinical studies suggest it may modulate dopaminergic and serotonergic systems, with reported protective effects against damage induced by cuprizone, MPTP, and other neurotoxins. The peptide has also shown potential in accelerating bone fracture healing and in counteracting the adverse effects of systemic corticosteroid administration.